Rossing, Peter
Bain, Stephen C.
Bosch-Traberg, Heidrun
Sokareva, Ekaterina
Heerspink, Hiddo J. L.
Rasmussen, Søren
Mellbin, Linda G.
Funding for this research was provided by:
Royal Library, Copenhagen University Library
Article History
Received: 15 May 2023
Accepted: 2 August 2023
First Online: 24 August 2023
Declarations
:
: PR received grants from AstraZeneca, Bayer, Novo Nordisk A/S, as well as consulting fees from AstraZeneca, Astellas, Bayer, Boehringer Ingelheim, Gilead, Merck, Mundipharma, Novo Nordisk A/S and Sanofi. SCB received grants, teaching sponsorship and honoraria from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck Sharp & Dohme, Novo Nordisk A/S, Pfizer, Sanofi and Takeda. HBT, ES and SR are employees of Novo Nordisk A/S, Denmark; HBT and SR also own stocks or stock options in Novo Nordisk A/S. HJLH received grants from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen and Novo Nordisk A/S; consulting fees from AstraZeneca, Bayer, Boehringer Ingelheim, Chinook, CSL Behring, Dimerix, Eli Lilly, Fresenius, Gilead, Janssen, Novo Nordisk A/S, Novartis and Travere Therapeutics; honoraria from AstraZeneca and Novo Nordisk A/S; travel and/or other support for attending meetings from AstraZeneca and Eli Lilly. LGM received grants, honoraria and consulting fees for advisory boards from Novo Nordisk A/S.
: The SUSTAIN 6 and PIONEER 6 trial protocols were approved by the institutional review board and ethics committee at each participating centre. All participants provided written informed consent.
: Not applicable.